omeprazole has been researched along with Necrosis in 17 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the effect of omeprazole (OPZ) and lansoprazole (LPZ) on the pathophysiology of myocardial necrosis in rats by inspecting a series of indicators like hemodynamic parameters, biochemical estimations and histopathological changes in the myocardial tissue." | 7.91 | Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in Wistar rats. ( Goyal, SN; Mahajan, UB; Ojha, S; Patil, AS; Patil, CR; Singh, AD, 2019) |
| "We investigated the effect of omeprazole (OPZ) and lansoprazole (LPZ) on the pathophysiology of myocardial necrosis in rats by inspecting a series of indicators like hemodynamic parameters, biochemical estimations and histopathological changes in the myocardial tissue." | 3.91 | Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in Wistar rats. ( Goyal, SN; Mahajan, UB; Ojha, S; Patil, AS; Patil, CR; Singh, AD, 2019) |
| "Percentage of flap necrosis was found to be less in all omeprazole received groups." | 3.85 | The Effect of Omeprazole Usage on the Viability of Random Pattern Skin Flaps in Rats. ( Çitil, R; Işik, VM; Koçer, U; Korkmaz, M; Oruç, M; Sadiç, M; Sayar, H; Şen, H, 2017) |
| "Omeprazole has a lethal effect over some cancer cells, and cell death is a key process in kidney disease." | 1.56 | Molecular pathways driving omeprazole nephrotoxicity. ( Cardenas-Villacres, D; Carrasco, S; Fontecha-Barriuso, M; Martín-Sanchez, D; Martinez-Moreno, JM; Ortiz, A; Ruiz-Ortega, M; Sanchez-Niño, MD; Sanz, AB, 2020) |
| "Pretreatment with lansoprazole 90 micromol/kg, given intraduodenally as single dose or once daily by intragastric route for 8 days, significantly prevented ethanol-HCl-induced gastric damage." | 1.32 | Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds. ( Blandizzi, C; Colucci, R; Del Tacca, M; Fornai, M; Lazzeri, G; Lubrano, V; Natale, G; Vassalle, C, 2004) |
| "Omeprazole was administered intraperitoneally, twice daily, for 3 days to male Wistar rats in two doses: 0." | 1.31 | Hepatic lysosomal enzymes activity and liver morphology after short-time omeprazole administration. ( Burdan, F; Maciejewski, R; Madej, B; Radzikowska, E; Siezieniewska, Z; Wojtowicz, Z, 2002) |
| "Pretreatment with naloxone almost completely blocked both fluid pooling effect and mucosal protective effect of loperamide." | 1.30 | Subcutaneous loperamide prevents gastric lesions induced by necrotizing agents in rats. ( Hatakeyama, Y; Ohtsuka, M; Shimomura, K; Tomoi, M, 1997) |
| "Timoprazole was an active antisecretory agent when given subcutaneously (ED50 10 mg/kg), but was not cytoprotective when given by this route." | 1.27 | Timoprazole is a unique cytoprotective agent in the rat. ( Davis, JP; Lancaster, C; Nezamis, JE; Nichols, NM; Ochoa, R; Rush, BD; Ruwart, MJ, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Roa Colomo, A | 1 |
| García Robles, A | 1 |
| Ruiz Escolano, E | 1 |
| Fontecha-Barriuso, M | 1 |
| Martín-Sanchez, D | 1 |
| Martinez-Moreno, JM | 1 |
| Cardenas-Villacres, D | 1 |
| Carrasco, S | 1 |
| Sanchez-Niño, MD | 1 |
| Ruiz-Ortega, M | 1 |
| Ortiz, A | 1 |
| Sanz, AB | 1 |
| Deliwala, SS | 1 |
| Gurvits, GE | 1 |
| Ozer, K | 1 |
| Çolak, Ö | 1 |
| Patil, AS | 1 |
| Singh, AD | 1 |
| Mahajan, UB | 1 |
| Patil, CR | 1 |
| Ojha, S | 1 |
| Goyal, SN | 1 |
| Şen, H | 1 |
| Oruç, M | 1 |
| Işik, VM | 1 |
| Sadiç, M | 1 |
| Sayar, H | 1 |
| Çitil, R | 1 |
| Korkmaz, M | 1 |
| Koçer, U | 1 |
| Castelluccio, MS | 1 |
| Hermida, R | 1 |
| Ayunta, H | 1 |
| Manzotti, L | 1 |
| Cháves, E | 1 |
| Romo, R | 1 |
| Perelstein, G | 1 |
| Hussain, A | 1 |
| Mahmood, H | 1 |
| Ansari, T | 1 |
| El-Hasani, S | 1 |
| Natale, G | 2 |
| Lazzeri, G | 1 |
| Lubrano, V | 1 |
| Colucci, R | 1 |
| Vassalle, C | 1 |
| Fornai, M | 1 |
| Blandizzi, C | 2 |
| Del Tacca, M | 2 |
| Ruwart, MJ | 1 |
| Nezamis, JE | 1 |
| Rush, BD | 1 |
| Lancaster, C | 1 |
| Davis, JP | 1 |
| Nichols, NM | 1 |
| Ochoa, R | 1 |
| Gherardi, G | 1 |
| Marveggio, C | 1 |
| Carignani, D | 1 |
| Hatakeyama, Y | 1 |
| Tomoi, M | 1 |
| Ohtsuka, M | 1 |
| Shimomura, K | 1 |
| Benoit, R | 1 |
| Grobost, O | 1 |
| Reichart, M | 1 |
| Busch, OR | 1 |
| Bruno, MJ | 1 |
| Van Lanschot, JJ | 1 |
| Katsinelos, P | 1 |
| Christodoulou, K | 1 |
| Pilpilidis, I | 1 |
| Papagiannis, A | 1 |
| Xiarchos, P | 1 |
| Tsolkas, P | 1 |
| Vasiliadis, I | 1 |
| Eugenidis, N | 1 |
| Martínez-Chamorro, C | 1 |
| Martínez, E | 1 |
| Gil-Fernández, JJ | 1 |
| Escudero, A | 1 |
| Acevedo, A | 1 |
| Fernández-Rañada, JM | 1 |
| Burdan, F | 1 |
| Siezieniewska, Z | 1 |
| Maciejewski, R | 1 |
| Madej, B | 1 |
| Radzikowska, E | 1 |
| Wojtowicz, Z | 1 |
3 reviews available for omeprazole and Necrosis
| Article | Year |
|---|---|
[Black esophagus related to acute esophageal necrosis: a new case].
Topics: Acute Disease; Anti-Ulcer Agents; Combined Modality Therapy; Duodenal Ulcer; Esophagoscopy; Esophagu | 1999 |
Black esophagus: an unusual finding during routine endoscopy.
Topics: Aged; Anti-Ulcer Agents; Biopsy; Esophagoscopy; Esophagus; Humans; Male; Mucous Membrane; Necrosis; | 2001 |
Acute necrotizing gastritis by Escherichia coli in a severely neutropenic patient.
Topics: Acute Disease; Amikacin; Anemia, Aplastic; Antilymphocyte Serum; Combined Modality Therapy; Cyclospo | 2002 |
14 other studies available for omeprazole and Necrosis
| Article | Year |
|---|---|
Black esophagus, is it as bad as it seems?
Topics: Alcoholism; Colonic Pseudo-Obstruction; Esophagitis; Esophagoscopy; Food, Formulated; Gastrointestin | 2019 |
Molecular pathways driving omeprazole nephrotoxicity.
Topics: Animals; Apoptosis; Cell Death; Humans; Kidney; Mice; Necrosis; Omeprazole; Oxidative Stress | 2020 |
Acute Esophageal Necrosis in a Patient With COVID-19.
Topics: Acute Disease; COVID-19; Drug Therapy, Combination; Endoscopy, Digestive System; Esophagus; Humans; | 2021 |
Discussion on the Effect of Omeprazole Usage on the Viability of Random Pattern Skin Flaps in Rats.
Topics: Animals; Graft Survival; Necrosis; Omeprazole; Rats; Rats, Sprague-Dawley; Rats, Wistar; Skin; Surgi | 2018 |
Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in Wistar rats.
Topics: Animals; Electrocardiography; Lansoprazole; Male; Malondialdehyde; Myocardial Infarction; Myocardium | 2019 |
The Effect of Omeprazole Usage on the Viability of Random Pattern Skin Flaps in Rats.
Topics: Animals; Female; Graft Survival; Image Interpretation, Computer-Assisted; Necrosis; Omeprazole; Post | 2017 |
[Upper gastrointestinal bleeding of infrequent cause].
Topics: Acute Disease; Aged, 80 and over; Ampicillin; Anti-Ulcer Agents; Esophagitis; Fatal Outcome; Gastroi | 2008 |
Pneumomediastinum, stomach wall and hepatic portal vein gas secondary to partial necrosis of the stomach wall.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; A | 2009 |
Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cyclooxygenase 1; Cyclooxygenas | 2004 |
Timoprazole is a unique cytoprotective agent in the rat.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Ethanol | 1984 |
Mechanisms of protection by omeprazole against experimental gastric mucosal damage in rats.
Topics: Animals; Ethanol; Gastric Acid; Gastric Mucosa; Gastritis; Hydrochloric Acid; Male; Misoprostol; Muc | 1995 |
Subcutaneous loperamide prevents gastric lesions induced by necrotizing agents in rats.
Topics: Animals; Ethanol; Gastric Mucosa; Hydrochloric Acid; Injections, Subcutaneous; Irritants; Loperamide | 1997 |
Black esophagus: a view in the dark.
Topics: Acute Disease; Aged; Anti-Ulcer Agents; Esophageal Diseases; Esophagus; Gastric Outlet Obstruction; | 2000 |
Hepatic lysosomal enzymes activity and liver morphology after short-time omeprazole administration.
Topics: Animals; Animals, Outbred Strains; beta-Galactosidase; Dose-Response Relationship, Drug; Enzyme Inhi | 2002 |